Amplification of MET occurs in ∼4% of lung cancer patients, with activation of MET signalling being associated with advanced cancer stage and shorter patient survival (Masuya et al, 2004; Zhao et al, 2005; Nakamura et al, 2007). Here, MET is linked to lung carcinoma.